Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness.
Immunogenicity of influenza vaccine in elderly people: a systematic review and meta-analysis of randomized controlled trials, and its association with real-world effectiveness.
复制标题
流感疫苗在老年人中的免疫原性：对随机对照试验的系统评价和荟萃分析，及其与现实世界有效性的关联。
DOI：
10.1080/21645515.2020.1747375
复制
发表时间：
2020-11-01
影响因子：
4.8
通讯作者：
Yang X
中科院分区：
文献类型：
--
作者：
Meng Z;Zhang J;Shi J;Zhao W;Huang X;Cheng L;Yang X
背景资料：老年人（≥60岁）特别容易感染流感病毒，疫苗可有效降低这一人群的疾病负担。然而，他们的抗体反应是否低于年轻人（18-60岁）仍然不清楚。因此，本荟萃分析旨在比较流感疫苗的免疫原性，并了解这两个年龄组之间流感疫苗与真实世界疫苗有效性（VE）的相关性。方法：进行了系统性文献检索，以识别2008年1月1日至2018年11月10日的相关研究。这些是随机对照试验，包括老年人样本，评估了在含胚鸡蛋中生产的灭活四价流感疫苗的免疫原性。我们排除了仅针对儿童或成人的研究。结果为血清保护率（SPR）和血清转换率（SCR）。结果：6项研究最终纳入本荟萃分析（7，976名参与者）。对于SPR，A/H1N1的合并风险比（RR）为0.92（95%CI：0.90-0.94，I2 = 66%，P < .0001），B/维多利亚为0.94（95%CI：0.90-0.98，I2 = 91%，P = .002），A/H3 N2和B/Yamagata的抗体应答在两个年龄组中相似。对于SCR，合并RR为0.85（95% CI：0.76-0.94，I2 = 93%，P = .003），0.77 A/H1N1、B/维多利亚和B/Yamagata的抗体应答分别为0.66-0.91（95%CI：0.66-0.91，I2 = 94%，P = 0.002）和0.83（95%CI：0.71-0.96，I2 = 94%，P = 0.02），A/H3 N2的抗体应答在两组中相似。流感疫苗接种后，不同病毒类型和亚型的抗体应答存在一定差异。结论：老年人对A/H1N1和B/维多利亚的SPR和SCR低于年轻人，而两个年龄组对A/H3 N2的抗体应答相似。对疫苗的抗体应答与真实世界的VE没有显著相关性，表明抗体应答可能不能完全反映A/H3 N2疫苗的有效性。
Background: Older people (≥60 years old) are particularly vulnerable to influenza virus infection, and vaccine is effective in reducing the disease burden in this population. However, it remains obscure whether their antibody response is lower than those of younger adults (18–60 years old). Thus, this meta-analysis was performed to compare the immunogenicity of influenza vaccines and understand their association with real-world vaccine effectiveness (VE) between these two age groups. Methods: A systematic literature search was conducted to identify relevant studies from Jan 01, 2008 to Nov 10, 2018. These are randomized controlled trials that included older adult samples, which assessed the immunogenicity of inactivated quadrivalent influenza vaccines produced in embryonated eggs. We excluded the studies focused only in children or adults. The outcomes were seroprotecton rate (SPR) and seroconversion rate (SCR). Results: Six studies were eventually included in the present meta-analysis (7,976 participants). For the SPR, the pooled risk ratio (RR) was 0.92 (95% CI: 0.90–0.94, I2 = 66%, P < .0001) for A/H1N1 and 0.94 (95% CI: 0.90–0.98, I2 = 91%, P = .002) for B/Victoria, and the antibody responses of A/H3N2 and B/Yamagata were similar in the two age groups. For the SCR, the pooled RR was 0.85 (95% CI: 0.76–0.94, I2 = 93%, P = .003), 0.77 (95% CI: 0.66–0.91, I2 = 94%, P = .002), and 0.83 (95% CI: 0.71–0.96, I2 = 94%, P = .02) for A/H1N1, B/Victoria and B/Yamagata, respectively, and the antibody responses of A/H3N2 were similar in the two groups. Some variations were found in the antibody responses across virus types and subtypes after influenza vaccination. Conclusion: The SPR and SCR of older adults were lower than those in younger adults for A/H1N1 and B/Victoria, while the two age groups had similar antibody responses for A/H3N2. The antibody responses to vaccines were not significantly associated with real-world VE, indicating that antibody response might not fully reflect the vaccine effectiveness of A/H3N2.
登录
查看更多内容
影响因子：
5.5
作者：
GOVAERT, TME;SPRENGER, MJW;KNOTTNERUS, JA
通讯作者：
KNOTTNERUS, JA
影响因子：
5.5
作者：
Greenberg, David P.;Robertson, Corwin A.;Decker, Michael D.
通讯作者：
Decker, Michael D.
影响因子：
5.5
作者：
McElhaney, Janet E.;Ewen, Catherine;Bleackley, R. Chris
通讯作者：
Bleackley, R. Chris
影响因子：
13.1
作者：
McElhaney, Janet E.
通讯作者：
McElhaney, Janet E.
DOI：
10.2807/1560-7917.es.2017.22.34.30602
发表时间：
2017-08-24
期刊：
Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
影响因子：
--
作者：
Domínguez A;Soldevila N;Toledo D;Godoy P;Espejo E;Fernandez MA;Mayoral JM;Castilla J;Egurrola M;Tamames S;Astray J;Morales-Suárez-Varela M;The Working Group Of The Project Pi/
通讯作者：
The Working Group Of The Project Pi/